Welcome to our dedicated page for Biophytis Sa SEC filings (Ticker: BPTSY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biophytis SA (BPTSY) SEC filings page provides access to the company’s reports as a foreign private issuer, primarily through Form 6‑K submissions under the Securities Exchange Act of 1934. These filings furnish English-language versions of Biophytis’ press releases, interim financial information, and other material updates related to its activities as a clinical-stage biotechnology company focused on age-related diseases.
Biophytis uses Form 6‑K to report events such as the release of its Interim Financial Report, the results of shareholder meetings, and key corporate or clinical milestones. Examples in the available filings include announcements about public funding for an obesity Phase 2 trial in Brazil, financing and launch plans for a Phase 3 trial in sarcopenia, and other partnership or development updates tied to its lead candidate BIO101 (20-hydroxyecdysone).
Through this page, users can review how Biophytis describes the progress of BIO101 in indications such as sarcopenia, obesity, COVID‑19–related respiratory disease, and ALS within its furnished documents. While Biophytis’ primary detailed financial statements and annual disclosures are filed separately, the Form 6‑K reports here offer timely snapshots of the company’s clinical, financial, and strategic developments.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of each document in plain language. This can help readers quickly understand the significance of interim financial reports, clinical trial announcements, or partnership disclosures without reading every page. Filings are updated as they are made available through EDGAR, allowing investors and researchers to follow Biophytis’ regulatory reporting history and key corporate communications linked to the BPTSY ticker.
Biophytis SA has signed a landmark agreement to create a Hong Kong–based joint venture, Biophytis Biopharmaceutical Holding LTD, to advance its BIO101 drug for sarcopenia in Asia. A consortium of Asian partners, including Ronghui Renhe Life Technology, has committed up to US$20 million over three years, with US$10 million expected in the first year and US$3 million at the joint venture’s creation.
Biophytis and its founders will own 29% of the joint venture, while Asian partners will hold 71%, with a board including three Biophytis representatives and two from the partners. The joint venture is expected to be created within 180 days and become operational in the first half of 2026. It will support an international Phase 3 trial, SARA-31, enrolling 942 patients to seek conditional marketing authorization for BIO101 in sarcopenia in Asia and Europe, starting in the second half of 2026 after regulatory approvals in China and Japan.
Biophytis SA’s shareholder disclosure shows that BlackRock Portfolio Management LLC has filed Amendment No. 1 to a Schedule 13G regarding its position in the company’s common stock. As of 12/31/2025, BlackRock Portfolio Management LLC reports beneficial ownership of 1,905,946 shares of Biophytis common stock, representing 4.8% of the outstanding class. All of these shares are reported with sole voting and sole dispositive power, with no shared power.
The filing explains that this reflects securities beneficially owned, or deemed beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries, and excludes other disaggregated business units. It also notes that various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares. BlackRock Portfolio Management LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Biophytis SA.
Biophytis S.A., a foreign private issuer based in Paris, submitted a Form 6-K to provide investors with its Interim Financial Report for the first half of fiscal year 2025. The company states that this interim report, dated October 31, 2025, is attached as Exhibit 99.1 and incorporated by reference, meaning the detailed financial and operational information for the period is contained in that exhibit.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 1,215,469 shares (5.2%) of Biophytis SA common stock. The filing indicates sole voting power over 1,215,469 shares and sole dispositive power over 1,215,469 shares, with no shared voting or dispositive power.
The event date is 09/30/2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The CUSIP is F1022R155. Item 6 notes that Kreos Capital VI (Expert Fund) LP has an interest in more than five percent of the company’s common stock.
Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.
Biophytis S.A. filed a Form 6-K to share a press release dated September 15, 2025. The company reports it has secured public funding in Brazil for an obesity phase 2 trial and has signed agreements with leading local clinical partners to conduct this study.